Baird analyst Brian Skorney raised the firm’s price target on Neurocrine to $152 from $148 and keeps an Outperform rating on the shares. The firm noted the company’s announcement that the Phase 3 trial of crinecerfont in adult CAH met its primary and several key secondary endpoints, and there were no treatment-related SAEs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine price target raised to $111 from $100 at BMO Capital
- Neurocrine announces ‘positive’ data from Phase 3 study of crinecerfont
- Neurocrine initiates Phase 1 study of NBI-1117570
- Neurocrine’s Ingrezza shows improvement in tardive dyskinesia study
- Neurocrine presents new INGREZZA capsules data
